Over the past decade, numerous prognostic factors influencing glioma patient outcome have been identified, including molecular markers such as IDH mutation status, the extent of resection, socioeconomic parameters, and evolving treatment modalities like targeted therapies such as Vorasidenib [1,10,11,12,13,21,22,23,24]. This evidence concerns the gene IDH2 and glioma.